Bridgefront Capital LLC Increases Stock Holdings in Bristol Myers Squibb Company $BMY

Bridgefront Capital LLC increased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 51.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 33,404 shares of the biopharmaceutical company’s stock after purchasing an additional 11,315 shares during the quarter. Bridgefront Capital LLC’s holdings in Bristol Myers Squibb were worth $1,507,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of BMY. Vanguard Group Inc. boosted its stake in Bristol Myers Squibb by 0.5% during the third quarter. Vanguard Group Inc. now owns 195,984,009 shares of the biopharmaceutical company’s stock worth $8,838,879,000 after buying an additional 1,058,803 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Bristol Myers Squibb by 16.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after acquiring an additional 10,195,775 shares during the period. Norges Bank purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at $1,554,154,000. Ameriprise Financial Inc. lifted its holdings in shares of Bristol Myers Squibb by 1.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock worth $1,508,099,000 after acquiring an additional 432,158 shares during the last quarter. Finally, Independent Franchise Partners LLP boosted its stake in shares of Bristol Myers Squibb by 20.6% during the 2nd quarter. Independent Franchise Partners LLP now owns 20,976,954 shares of the biopharmaceutical company’s stock worth $971,023,000 after purchasing an additional 3,583,163 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. HSBC reiterated a “hold” rating and set a $53.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Barclays assumed coverage on Bristol Myers Squibb in a research report on Thursday, February 19th. They set an “overweight” rating and a $75.00 target price for the company. UBS Group reaffirmed a “buy” rating and set a $70.00 target price on shares of Bristol Myers Squibb in a research note on Friday, March 6th. Royal Bank Of Canada started coverage on Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price target on the stock. Finally, Citigroup raised their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. Nine equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and an average target price of $61.00.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $59.02 on Friday. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The stock has a market cap of $120.18 billion, a price-to-earnings ratio of 17.11, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. The firm has a 50-day moving average of $58.24 and a two-hundred day moving average of $51.43. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same period last year, the business posted $1.67 earnings per share. The business’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.3%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.